Results 11 to 20 of about 178,854 (310)
Reverse Transcriptase Inhibitors as Microbicides
The CAPRISA 004 study in South Africa has accelerated the development of vaginal and rectal microbicides containing antiretrovirals that target specific enzymes in the reproduction cycle of HIV, especially reverse transcriptase inhibitors (RTI). In this review we discuss the potential relevance of HIV-1 RTIs as microbicides, focusing in the nucleotide ...
Lewi, P. +7 more
openaire +5 more sources
Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability
Considering the undesirable metabolic stability of our recently identified NNRTI 5 (t1/2 = 96 min) in human liver microsomes, we directed our efforts to improve its metabolic stability by introducing a new favorable hydroxymethyl side chain to the C-5 ...
Ya-Li Sang +4 more
doaj +1 more source
Sufficient drug concentrations are required for efficacy of antiretroviral drugs used in HIV care and prevention. Measurement of nucleotide analogs, included in most HIV medication regimens, enables monitoring of short‐ and long‐term adherence and the ...
Ayokunle O. Olanrewaju +7 more
doaj +1 more source
Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations
Long-acting (LA) anti-HIV regimens show promise for increasing dosing intervals and consequently, improving the patients’ quality of life. The first FDA-approved LA therapy is Cabenuva, which comprises rilpivirine (a non-nucleoside reverse transcriptase ...
Maria E. Cilento +3 more
doaj +1 more source
Small Dumbbell Oligonucleotides Inhibitors of RNase H Activity of MOMULV Reverse Transcriptase
The small dumbbell oligonucleotides containing loops of phosphodiester (OL-1), two trimethylene, C3 moieties in each loop (OL-2) and phosphorothioate (OL-3) linkages were synthesized.
Ajay Kumar
doaj +1 more source
Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
Although tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have been evaluated in various clinical trials, limited safety and efficacy data exist in real-world settings.
Sarah M Michienzi +6 more
doaj +1 more source
Resistance against Reverse Transcriptase Inhibitors [PDF]
The response to antiretroviral therapy in human immunodeficiency virus (HIV)-infected patients is limited by the emergence of drug resistance. This resistance is a consequence of the high rate of HIV mutation, the high rate of viral replication (especially when potent multidrug therapies are not used or taken reliably), and the selective effect of ...
openaire +2 more sources
Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus ...
Niccolò Riccardi MD +3 more
doaj +1 more source
Identification of a 3-aminoimidazo[1,2-a]pyridine inhibitor of HIV-1 reverse transcriptase
Background Despite the effectiveness of highly active antiretroviral therapy (HAART), there remains an urgent need to develop new human immunodeficiency virus type 1 (HIV-1) inhibitors with better pharmacokinetic properties that are well tolerated, and ...
Elleder Daniel +6 more
doaj +1 more source
A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity.
Telomerase, a unique reverse transcriptase that specifically extends the ends of linear chromosomes, is up-regulated in the vast majority of cancer cells.
Wilnelly Hernandez-Sanchez +8 more
doaj +1 more source

